Endocrine Abstracts

Gliomas are derived from glial-cells and are the most common primary brain tumor, characterized by rapid growth and invasion. Astrocytomas are a subset of malignant gliomas which are classified, based on their agresiveness features, in low grades (I and II) to high grades (HGAs; III and IV), being grade-IV (glioblastoma multiforme; GBM) the most malignant and aggressive type. Current standard treatment for GBMs consists on surgery followed by radiotherapy/chemotherapy; however...

Background: Gliomas are the most common primary brain tumor, being astrocytomas a subset of malignant gliomas graded on a scale of I to IV. Grade-IV astrocytomas (glioblastoma multiforme; GBM) are the most malignant and aggressive type. Current standard treatments are ineffective, being their average postoperative survival of 12-16 months. Therefore, there is a clear need for the identification of novel therapeutic targets to treat this pathology. In this context, the truncate...

Astrocytomas are a subtype of malignant gliomas characterized by rapid growth and high diffusion through the brain. Based on the agresiveness features, they are stratified from low grades (I and II) to high grades (HGAs; III and IV), being grade-IV [glioblastoma multiforme (GBM)] the most aggressive and one of the most common malignant cancers in the brain, with an overall survival from diagnosis of ~14 months. Current standard therapies to treat HGAs are not efficient and the...

Background: Glioblastomas (GBMs) remain the deadliest human brain tumors, with a poor prognosis despite years of research. Currently, standard therapeutic strategies to treat GBM are not efficient, and the overall survival is ˜14 months. Thus, the identification of new therapeutic tools to battle GBMs is crucial. In this sense, many metabolic drugs (e.g., metformin (MF) and simvastatin (SVT)) have emerged as putative antitumor agents for certain endocrine-related cancers,...